Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Three settings, one goal: Performance of different HIV testing strategies at a tertiary centre in Milan.

HIV medicine·2026
Same author

Changing Clinical and Laboratory Characteristics of Progressive Multifocal Leukoencephalopathy: A Retrospective National Cohort Study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025
Same author

Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy.

AIDS (London, England)·2024
Same author

No need to modify treatment within the first month after rapid start of a tailored antiretroviral therapy: the TWODAY Study.

The new microbiologica·2023
Same author

Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials.

EClinicalMedicine·2023
Same author

Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor-based regimen.

International journal of antimicrobial agents·2023

相关实验视频

Updated: Jun 30, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 10, 2014

在Tipranavir (RESIST)

Charles B Hicks1, Pedro Cahn, David A Cooper

  • 1Division of Infectious Diseases and International Health, Duke University Medical Center, Durham, NC 27710, USA. charles.hicks@duke.edu

Lancet (London, England)
|August 8, 2006
PubMed
概括

提普拉纳维尔 - 里托纳维尔在严重预先治疗的HIV-1患者中显示出比较蛋白酶抑制剂 - 里托纳维尔更高的疗效. 这种新型蛋白酶抑制剂在具有挑战性的患者群体中提供了改善的病毒学和免疫学反应.

更多相关视频

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

相关实验视频

Last Updated: Jun 30, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 10, 2014

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

科学领域:

  • * 病毒学和免疫学
  • *药理学和治疗学 *药理学和治疗学

背景情况:

  • * 对于HIV-1感染者而言,仅有有限的治疗选择,他们先前接受了广泛的抗逆转录病毒疗法.
  • *以前的蛋白酶抑制剂疗法和耐药性需要新的治疗策略.

研究的目的:

  • * 为了比较tipranavir-ritonavir加上优化后台治疗方案的疗效和安全性,与比较蛋白酶抑制剂-ritonavir在严重预先治疗的HIV-1患者中进行比较.
  • *为了评估48周的病毒学和免疫学反应.

主要方法:

  • * 综合分析了来自两个跨国,随机,开放标签,III期RESIST研究的48周数据.
  • * 纳入标准:HIV-1RNA≥1000副本/毫升,≥3个月的三重类经验,≥2个蛋白酶抑制剂疗法和基因型蛋白酶抑制剂耐药性.
  • * 主要终点:治疗反应的比例和48周治疗失败的时间.

主要成果:

  • * 与CPI-利托纳维尔相比,提普拉纳维尔-利托纳维尔的治疗应答率显著更高 (33.6%与15.3%,p<0.0001),治疗失败的中位时间更长 (113天与0天,p<0.0001).
  • * 在tipranavir-ritonavir组观察到更高的治疗坚持率 (65.1%对26.1%).
  • *胃肠道疾病和肝酶,胆固醇和甘油三酸的升高在提普拉纳维尔 - 里托纳维尔治疗中更频繁.

结论:

  • *提普拉纳维尔 - 里托纳维尔,结合一个优化的背景疗法,在48周的时间内,在接受广泛的先前抗逆转录病毒治疗的患者中,提供了卓越的病毒学和免疫学益处.
  • * 蒂普拉纳维尔-里托纳维尔代表了治疗经验丰富的HIV-1患者的治疗,具有蛋白酶抑制剂耐药性的一个有价值的治疗选择.